Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial

BACKGROUND: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti–IL-6R monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivapalasingam, Sumathi, Lederer, David J, Bhore, Rafia, Hajizadeh, Negin, Criner, Gerard, Hosain, Romana, Mahmood, Adnan, Giannelou, Angeliki, Somersan-Karakaya, Selin, O’Brien, Meagan P, Boyapati, Anita, Parrino, Janie, Musser, Bret J, Labriola-Tompkins, Emily, Ramesh, Divya, Purcell, Lisa A, Gulabani, Daya, Kampman, Wendy, Waldron, Alpana, Ng Gong, Michelle, Saggar, Suraj, Sperber, Steven J, Menon, Vidya, Stein, David K, Sobieszczyk, Magdalena E, Park, William, Aberg, Judith A, Brown, Samuel M, Kosmicki, Jack A, Horowitz, Julie E, Ferreira, Manuel A, Baras, Aris, Kowal, Bari, Thomas DiCioccio, A, Akinlade, Bolanle, Nivens, Michael C, Braunstein, Ned, Herman, Gary A, Yancopoulos, George D, Weinreich, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903479/
https://www.ncbi.nlm.nih.gov/pubmed/35219277
http://dx.doi.org/10.1093/cid/ciac153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903479/
https://www.ncbi.nlm.nih.gov/pubmed/35219277
http://dx.doi.org/10.1093/cid/ciac153

Ejemplares similares